MASH (Metabolic Liver Disease): FDA Accelerated Approval in 2025 Metabolic dysfunction-associated steatohepatitis (MASH) is a condition where excess fat in the liver leads to inflammation and progressive fibrosis
Our findings align with the previous meta-analysis done by Avogaro et al., which specifies improvement in NT-ProBNP level by GLP-1RA drugs.20 Also, our findings strengthen the findings in secondary analysis of STEP-HFpEF and STEP-HFpEF DM trials by Petrie et al., where they concluded similar improvements.21 The KCCQ-CSS score assesses patients health perceptions, encompassing physical restrictions, symptoms, social limitations, and quality of life, and is crucial for HFpEF patients.22 A change of 5 points is considered clinically meaningful.23 Our meta-analysis found that GLP-1RA therapy considerably improves quality of life, as shown by higher KCCQ-CSS scores
When choosing a glutathione supplement to detox, ensure that you choose products that have high absorption rates
Other A recent study found that they may also help delay the progression of chronic kidney disease, which often develops in people with type 2 diabetes
